加拿大阿尔伯塔省无细胞百日咳疫苗效果与免疫衰减:2010-2015年CIRN研究
该研究采用检测阴性设计,纳入2010年1月1日至2015年8月31日期间在加拿大阿尔伯塔省接受百日咳鲍特菌实时PCR检测的所有人员,从该省免疫登记库获取接种史,采用多变量logistic回归估计调整比值比并计算疫苗效果。结果显示,接种无细胞百日咳疫苗后1年疫苗效果为90%(95%CI 87-92%),1-3年为81%(95%CI 77-85%),4-7年为76%(95%CI 68-82%),8年及以上降至37%(95%CI 11-56%)。结论认为疫苗效果在接种后第一年最高,随后随接种时间延长明显下降,提示大量青少年和成人对百日咳鲍特菌易感,可能需要在儿童期、青少年期和孕期定期加强接种。
要点
- 接种无细胞百日咳疫苗后1年疫苗效果为90%,8年及以上降至37%。
- 疫苗效果随末次接种后时间延长而明显下降。
- 结果提示大量青少年和成人对百日咳鲍特菌易感。
核心结论
- 无细胞百日咳疫苗效果在接种后第一年最高,随后随末次接种后时间延长而明显下降。
- 研究结果提示大量青少年和成人对百日咳鲍特菌感染易感。
研究设计与样本
- 研究采用检测阴性设计,纳入2010年1月1日至2015年8月31日在加拿大阿尔伯塔省接受百日咳鲍特菌实时PCR检测的所有人员。
- 接种史来自阿尔伯塔省免疫登记库,按该省接种程序将接种状态分为全程、不完整或未接种,曾接种至少1剂全细胞疫苗者被排除。
- 采用多变量logistic回归估计调整比值比(aOR)及95%CI,并调整接种状态、年龄、性别、社区收入、城乡状态和合并症情况,疫苗效果按[(1-aOR)×100]计算。
主要发现
- 共12,149份检测中936份(7.7%)为百日咳鲍特菌阳性。
- 末次接种无细胞百日咳疫苗后1年疫苗效果为90%(95%CI 87-92%)。
- 末次接种后1-3年疫苗效果为81%(95%CI 77-85%)。
- 末次接种后4-7年疫苗效果为76%(95%CI 68-82%)。
- 末次接种后8年及以上疫苗效果为37%(95%CI 11-56%)。
临床怎么用
- 应关注无细胞百日咳疫苗免疫随时间的衰减,尤其在末次接种多年后的人群中。
- 研究结果提示可能需要在儿童期、青少年期和孕期定期进行加强接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pertussis is still frequently reported in Canada. In Alberta, pertussis incidence ranged from 1.8 to 20.5 cases per 100,000 persons for 2004-2015. Most cases occurred in those aged <15 years. In Alberta, acellular formulations replaced whole-cell in 1997. We investigated pertussis vaccine effectiveness (VE) using a test-negative design (TND) study. METHODS: We included all persons who had a real-time PCR laboratory test for Bordetella pertussis between January 1, 2010 and August 31, 2015, in the province of Alberta, Canada. Vaccination history was obtained from Alberta's immunization repository. Vaccination status was classified as complete, incomplete, or unvaccinated, based on the province's vaccination schedule. Persons who had received ≥one dose of whole cell vaccine were excluded from analysis. Multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for pertussis infection by time since last vaccination. We adjusted for vaccination status, age, sex, neighbourhood income, urban/rural status, and the presence of a co-morbid condition. VE was calculated as [(1 - aOR) * 100]. RESULTS: Of the 12,149 tests available, 936 (7.7%) were positive for Bordetella pertussis. Among the full cohort, VE was 90% (95% CI 87-92%) at 1 year, 81% (95% CI 77-85%) at 1-3 years, 76% (95% CI 68-82%) at 4-7 years, and 37% (95% CI 11-56%) at 8 or more years since a last dose of acellular pertussis vaccine. CONCLUSIONS: Pertussis VE was highest in the first year after vaccination, then declined noticeably as years since a last vaccination increased. Our results suggest that a large number of adolescents and adults are susceptible to infection with Bordetella pertussis. Regular boosters throughout childhood, adolescence, and during pregnancy may be needed.
引用
- Bell CA, Russell ML, Drews SJ, et al. Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010-2015, a Canadian Immunization Research Network (CIRN) study. Vaccine. 2019. PMID: 31164304. doi:10.1016/j.vaccine.2019.05.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。